REG - ValiRx PLC - Change of Registered Address
RNS Number : 9521EValiRx PLC09 July 2019
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Change of Registered Address
London, UK, 09 July 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that its registered office address has changed to Stonebridge House, Chelmsford Road, Hatfield Heath, England, CM22 7BD with effect from today.
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka, Chief Executive
Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.
Tel: +44 (0) 7879 458 364
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: +44 (0) 20 7213 0880
Novum Securities Limited
Colin Rowbury
Tel: +44 (0) 20 7399 9400
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDCROEAEXNEENNEFF
Recent news on ValiRx
See all newsREG - ValiRx PLC - Directorate Change
AnnouncementREG - ValiRx PLC - Investor Webinar
AnnouncementREG - ValiRx PLC - Inaphaea Co-Marketing Agreement
AnnouncementREG - ValiRx PLC - Half-year Report
AnnouncementREG - ValiRx PLC - Conclusion of Evaluation Project
Announcement